Skip to content

Neuronetics STIM Return on equity

Return on equity at other companies

LifeStance Health Group logo
LifeStance Health GroupLFST
1.6%+1.0pp
Stereotaxis logo
StereotaxisSTXS
-251.5%-29.9pp
Neuropace, Inc. logo
Neuropace, Inc.NPCE
-111.4%-13.1pp
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
22.5%+10.1pp
ClearPoint Neuro logo
ClearPoint NeuroCLPT
-149.7%+4,074pp
Orthofix Medical Inc. logo
Orthofix Medical Inc.OFIX
-13.4%-4.6pp

Other financials

Income statement

See full
Revenue$34.5M+7.8%
Gross profit$16.2M+2.6%
Operating income-$9.0M+18.3%
Net income-$10.8M+14.9%
EPS (diluted)-$0.16+23.8%

Balance sheet

See full
Cash & equivalents$13.2M-34.7%
Total debt$85.4M+3.5%
Total equity$13.3M-62.6%
Total assets$125.4M-11.7%

Cash flow

See full
Operating cash flow-$9.4M+44.6%
CapEx$197.0K-10.0%
Free cash flow-$9.6M+44.1%

Valuation

See full
Market cap$90.46M-59.6%
Enterprise value$162.64M-44.6%
P/S0.6×-1.4×

Profitability

See full
Gross margin48%-15.6pp
Operating margin-19.4%-6.9pp
Net margin-24.5%-8.7pp
FCF margin-9.4%-4.1pp

Returns & leverage

See full
Debt / equity6.4×+4.1×
Current ratio1.7×-0.8×

Where this comes from

Calculated from Neuronetics’s reported figures.

Based on trailing twelve months.

The official record: Neuronetics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Neuronetics's return on equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Neuronetics's return on equity?
Neuronetics (STIM) reported return on equity of -152.4% in Q1 2026.
How has Neuronetics's return on equity changed year-over-year?
Neuronetics's return on equity increased by 0.9% year-over-year, from -153.7% to -152.4%.
What is the long-term trend for Neuronetics's return on equity?
Over 5 years (2020 to 2025), Neuronetics's return on equity has grown at a 15.8% compound annual growth rate (CAGR), from -74.9% to -155.7%.
What does return on equity mean?
Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.